Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Galectin Therapeutics ( (GALT) ).
On June 16, 2025, Galectin Therapeutics announced a presentation on Belapectin, highlighting its potential to address MASH cirrhosis and portal hypertension, which lack FDA-approved treatments. The presentation detailed Belapectin’s efficacy in reducing portal pressure and preventing esophageal varices, positioning it as a promising therapy in a high-risk and underserved market. The announcement underscores the company’s strategic focus on addressing significant unmet needs in liver disease treatment, potentially impacting its market positioning and offering hope to stakeholders involved in managing MASH cirrhosis.
The most recent analyst rating on (GALT) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.
Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Galectin Therapeutics operates in the biotechnology industry, focusing on developing therapies for fibrotic diseases and cancer. Its primary product, Belapectin, is a galectin-3 inhibitor aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension, conditions with significant unmet medical needs.
Average Trading Volume: 206,288
Technical Sentiment Signal: Sell
Current Market Cap: $86.71M
See more data about GALT stock on TipRanks’ Stock Analysis page.